Allergan and GSK in distribution agreements

Under the terms of the agreement, Allergan will license to GSK all clinical development and commercial rights to Botox in Japan and China, markets in which GSK has extensive commercial, regulatory and R&D resources, as well as expertise in neurology.

Allergan believes that these additional resources should accelerate new indications for Botox and maximize the product’s sales potential in those important markets. Allergan will receive an up-front payment, payments for R&D and marketing support, and royalties on Japan and China Botox sales.

In addition, Allergan has obtained the right to co-promote GSK’s products Imitrex STATdose System and Amerge in the US to neurologists for a 5-year period.

Imitrex STATdose system is approved for the treatment of acute migraine in adults and for the acute treatment of cluster headache episodes. Amerge Tablets are approved for the acute treatment of migraine attacks with and without an aura in adults. Allergan will receive both fixed and performance payments from GSK.

“In China, GSK will establish a presence for Botox as the product has not as of yet been commercially available in this market,” said David Pyott, chairman, president and chief executive officer of Allergan. “Second, the co-promotion of GSK’s Imitrex STATdose System and Amerge in the US fulfills our strategic goal of expansion in the key neurology market and allows us to gain valuable expertise in the headache/migraine segments as we enter into phase III clinical trials exploring the use of Botox for the treatment of chronic daily headache.”